Sign In
Buy ATNM
$0.84
-0.0001 (-0.0119%)
At Close: Jul 31, 2026
ATHENS, Greece & BELOIT, Wisc.--(BUSINESS WIRE)--BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research, today announced a strategic supply
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
07:42am, Tuesday, 17'th Feb 2026
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted
Reviewing Actinium Pharmaceuticals (NYSE:ATNM) & Aadi Bioscience (NASDAQ:AADI)
01:31am, Thursday, 22'nd Jan 2026
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Aadi Bioscience (NASDAQ: AADI - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare
Actinium Pharmaceuticals (NYSE:ATNM) & ProMetic Life Sciences (OTCMKTS:PFSCF) Head to Head Comparison
02:22am, Saturday, 10'th Jan 2026
ProMetic Life Sciences (OTCMKTS:PFSCF - Get Free Report) and Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will
Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?
10:41am, Monday, 22'nd Dec 2025
Here is how Actinium Pharmaceuticals (ATNM) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
08:45am, Friday, 12'th Dec 2025
- ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and
Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Down 0.7% – Here’s Why
02:26am, Thursday, 11'th Dec 2025
Actinium Pharmaceuticals, Inc. (NYSE: ATNM - Get Free Report)'s stock price dropped 0.7% on Wednesday. The stock traded as low as $1.41 and last traded at $1.42. Approximately 155,911 shares traded ha
Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment options ATNM-400 overcomes HER2 therapy resistance and represents a
The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet
08:30am, Monday, 17'th Nov 2025
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 17, 2025) - Investorideas.com, a go-to investing platform covering biotech and pharma stocks issues a snapshot looking at th
- New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment
- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC DATROWAY®)
- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology withcontinued expression following androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy, enabling p
ATNM-400 is advancing as a first-in-class, multi-tumor Actinium-225 radiotherapy candidate with activity across prostate and lung cancers, two of the largest cancer indications globally New preclinica
- ATNM-400 targets a highly differentiated, non-PSMA antigen associated with the development and progression of prostate cancer, exhibiting potent therapeutic activity independent of PSMA expressi
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
10:41am, Tuesday, 02'nd Sep 2025
Here is how Actinium Pharmaceuticals (ATNM) and Avadel (AVDL) have performed compared to their sector so far this year.
